Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals (CRVS) PT Lowered to $7 at Oppenheimer

March 20, 2024 4:38 AM EDT

Oppenheimer analyst Jeff Jones lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $7.00 (from $8.00) while maintaining a Outperform rating.

The analyst comments "On Tuesday CRVS announced 4Q and full-year results, highlighting a somewhat narrowed plan for lead candidate soquelitinib. Management is... More